Abstract:Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode of action has advanced completely through clinical development to market. In this study, we present findings on the cyclophilin inhibitor, CRV431, that highlight its potential as a drug candidate for chronic liver diseases. CRV431 was found to potently inhibit all cyclophilin isoforms tested—A, B, D, and G. Inhibitory constant or IC50 values ranged from 1 to 7 nM, which was up to 13 times more potent than the parent compound, cyclosporine A (CsA), from which CRV431 was derived. Other CRV431 advantages over CsA as a nontransplant drug candidate were significantly diminished immunosuppressive activity, less drug transporter inhibition, and reduced cytotoxicity potential. Oral dosing to mice and rats led to good blood exposures and a 5- to 15-fold accumulation of CRV431 in liver compared with blood concentrations across a wide range of CRV431 dosing levels. Most importantly, CRV431 decreased liver fibrosis in a 6-week carbon tetrachloride model and in a mouse model of nonalcoholic steatohepatitis (NASH). Additionally, CRV431 administration during a late, oncogenic stage of the NASH disease model resulted in a 50% reduction in the number and size of liver tumors. These findings are consistent with CRV431 targeting fibrosis and cancer through multiple, cyclophilin-mediated mechanisms and support the development of CRV431 as a safe and effective drug candidate for liver diseases.SIGNIFICANCE STATEMENTCyclophilin inhibitors have demonstrated therapeutic activities in many disease models, but no drug candidates have yet advanced completely through development to market. In this study, CRV431 is shown to potently inhibit multiple cyclophilin isoforms, possess several optimized pharmacological properties, and decrease liver fibrosis and tumors in mouse models of chronic liver disease, which highlights its potential to be the first approved drug primarily targeting cyclophilin isomerases.

Recent Progress and Prospects of the Study of Cyclophilins

The Progress of Cyclophilin A in Cancer Research

Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers

Cyclophilin A: promising target in cancer therapy

The Role of Cyclophilins in Viral Infection and the Immune Response

Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases

Cyclophilin A: a key player for etiological agent infection

Biochemical Features of Recombinant Human Cyclophilin J

Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID 19

Evaluating the potential of non-immunosuppressive cyclosporin analogs for targeting Toxoplasma gondii cyclophilin: Insights from structural studies

Characterizing the folding core of the cyclophilin A - cyclosporin A complex I: hydrogen exchange data and rigidity analysis

Structure of recombinant human cyclophilin J, a novel member of the cyclophilin family.

Depletion of cyclophilins B and C leads to dysregulation of endoplasmic reticulum redox homeostasis

Cyclophilin J Limits Inflammation Through the Blockage of Ubiquitin Chain Sensing.

Crystallization and Preliminary X-ray Crystallographic Studies of Human Cyclophilin J.

Emerging role of cyclophilin A in HIV-1 infection: from producer cell to the target cell nucleus

Discovery of a Potent Peptidic Cyclophilin A Inhibitor Trp-Gly-Pro

Discovering Novel Chemical Inhibitors of Human Cyclophilin A: Virtual Screening, Synthesis, and Bioassay

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models

First Characterization of Three Cyclophilin Family Proteins in the Oyster, Crassostrea Ariakensis Gould.